AI‐driven patient selection can drastically reduce sample sizes in Alzheimer's disease clinical trials
An AI-driven patient selection method can drastically reduce the sample size and cost of a trial by at least 20%, while maintaining statistical power, thereby accelerating therapeutic development by enabling more cost-effective trials.
Authors
- Christian Dansereau (ORCID: https://orcid.org/0000-0003-3363-1901)
- César Laurent
- Adrián Noriega de la Colina
- Angela Tam
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_100413
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00